drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Engineered universal T-cell therapy expressing a chimeric NK receptor that enables NK-like recognition of stress-induced NK ligands on dysregulated/activated immune cells. Engagement triggers T-cell activation, perforin/granzyme-mediated cytotoxicity, and immunomodulation to eliminate pathogenic immune cells driving steroid-refractory/resistant or steroid-dependent GVHD. Administered IV in Phase 1 SAD/MAD dosing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Engineered universal T cells expressing a chimeric NK receptor (NK-like CAR, e.g., NKG2D-based) that recognizes stress-induced NK ligands on activated/dysregulated immune cells; receptor engagement triggers T-cell activation with perforin/granzyme-mediated cytotoxicity and immunomodulation to eliminate pathogenic alloreactive T cells and antigen-presenting cells driving steroid-refractory/resistant GVHD.
drug_name
Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
nct_id_drug_ref
NCT06568328